New combo aims to boost breast cancer treatment before chemo

NCT ID NCT07188246

Recruiting now Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times

Summary

This study tests a new approach for people with stage 2 or 3 breast cancer. Before standard chemotherapy, participants receive targeted radiation and an immunotherapy drug (pembrolizumab) injected into the tumor. The goal is to see if this combination can improve the chance of eliminating all cancer cells before surgery. About 40 adults with invasive breast cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

St. Joseph's Health Care London
NOT_YET_RECRUITING

London, Ontario, N6A 4V2, Canada
St. Joseph's Health Care London
RECRUITING

London, Ontario, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER BREAST CANCER INVASIVE BREAST CANCER STAGE II BREAST CANCER STAGE III BREAST CANCER TRIPLE NEGATIVE BREAST CANCER TRIPLE NEGATIVE